First and Only:
AI-derived tool to provide AlloSure-integrated view of rejection risk
Validated to provide risk assessment in a real world clinical setting
Available with AlloSure Kidney
AlloView is intended to support the healthcare provider’s independent assessment of the patient’s post transplant status. AlloView is not intended to diagnose a condition or determine a patient’s course of treatment. Clinical decisions should be based on the totality of clinical evidence, within the context of an overall clinical assessment of the individual patient and within the scope of the health care provider’s training and experience. AlloView is intended to provide an integrated view to help clinicians interpret CareDx’s proprietary laboratory developed test (LDT), AlloSure Kidney. A test result from a CareDx dd-cfDNA test is a required input of AlloView. AlloView results are clinically validated only in this context.
iBox is an integrative model that provides prediction of an individual’s risk of transplant loss at 3, 5, and 7 years.
iBox results may be used for:
Early identication of patients at-risk for graft loss
Evaluating the impact of short term clinical events (rejection, immunosuppression changes, etc.) on long term graft survival
iBox provides clinicians with an integrative risk prediction to inform the assessment of kidney allograft survival at 3-, 5-,and 7-years post-transplant. As a prognostic tool, iBox is intended to support the healthcare provider’s independent assessment of the patient’s post-transplant status. It is not intended to diagnose a condition or determine a patient’s course of treatment. Clinical decisions should be based on the totality of clinical evidence, within the context of an overall clinical assessment of the individual patient and within the scope of the health care provider’s training and experience.
Case Study 1: Clinical Utility of AlloView with Dr. Sapna Shah
Case Study 2: Clinical Utility of AlloView with Dr. Sapna Shah